Clinical Trials Browser

Gliosarcoma × Colony-Stimulating Factors × 90 days × Clear all

NCT02455557 2026-03-30

SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma

Phase 2 Active not recruiting

66 enrolled 11 charts

Glioblastoma, Gliosarcoma